NWBO Stock Facing Uptrend Towards $1 Value

Combating covid-19 was awful for any vaccine maker that had no time to carefully test the candidates. However, cancer-fighting drugs could give a longer time to develop and manufacture. Northwest Therapeutics has had enough duration to create DCVax and produce it massively for any open markets that need oncology-based medicines.

Two months ago Northwest could get clear approval to manufacture its products in the UK. Some hope has lit in the dark tunnel after an extremely long journey to produce the cancer treatment drugs. This year NWBO could stay stable and has grown slowly from $0.7754 to $0.9180 on an average volume of 2,417,935 shares. The EPS is still negative at $0.3880 per share.